NCT04711265View on ClinicalTrials.gov

Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys

CompletedOBSERVATIONAL
Enrollment

176

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

January 31, 2019

Conditions
HPV VaccineHPV InfectionHIV-1-infection
Interventions
DRUG

Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine

Intramuscular injection with 3 doses of QHPV

Trial Locations (1)

Unknown

Partners in Health Research and Development, Thika

Sponsors
All Listed Sponsors
collaborator

University of Washington

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Kenya Medical Research Institute

OTHER